Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise

Executive Summary

Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.

You may also be interested in...



FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access

Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.

Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent

Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.

Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme

FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel